

General information about company	
Scrip code	524606
Name of company	BERYL DRUGS LTD
Result Type	Main Format
Class of security	Equity
Date of start of financial year	01-04-2016
Date of end of financial year	31-03-2017
Date of board meeting when results were approved	05-11-2016
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	28-10-2016
Description of presentation currency	INR
Level of rounding used in financial results	Thousands
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical Industrty

Quarterly & Half Yearly Financial Result by Companies Other than Banks							
Particulars		3 months ended (dd-mm-yyyy)	Previous 3 months ended (dd-mm-yyyy)	Corresponding 3 months ended in the previous year (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	Year to date figures for previous period ended (dd-mm-yyyy)	Previous accounting year ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2016	01-04-2016	01-07-2015	01-04-2016	01-04-2015	01-04-2015
B	Date of end of reporting period	30-09-2016	30-06-2016	30-09-2015	30-09-2016	30-09-2015	31-03-2016
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalone
Part I							
1	Revenue From Operations						
	Net sales or Revenue from Operations	29994	30400	40538	60394	86575	131102
	Other operating revenues	352	561	821	913	1380	3711
	Total Revenue from operations (net)	30346	30961	41359	61307	87955	134813
2	Expenses						
(a)	Cost of materials consumed	25132	23292	25243	48424	64117	88047
(b)	Purchases of stock-in-trade	0	0	0	0	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-2433	504	0	-1929	0	-1947
(d)	Employee benefit expense	2520	2596	3470	5116	5740	12092
(e)	Depreciation and amortisation expense	1000	1000	1250	2000	2050	4101
(f)	Other Expenses						
1	others	2374	1610	8887	3984	11660	27759
	Total other expenses	2374	1610	8887	3984	11660	27759
	Total expenses	28593	29002	38850	57595	83567	130052

Quarterly & Half Yearly Financial Result by Companies Other than Banks							
Particulars		3 months ended (dd-mm-yyyy)	Previous 3 months ended (dd-mm-yyyy)	Corresponding 3 months ended in the previous year (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	Year to date figures for previous period ended (dd-mm-yyyy)	Previous accounting year ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2016	01-04-2016	01-07-2015	01-04-2016	01-04-2015	01-04-2015
B	Date of end of reporting period	30-09-2016	30-06-2016	30-09-2015	30-09-2016	30-09-2015	31-03-2016
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalone
Part I							
3	Profit (loss) from operations before other income, finance costs and exceptional items	1753	1959	2509	3712	4388	4761
4	Other income	0	0	0	0	0	0
5	Profit (loss) from ordinary activities before finance costs and exceptional items	1753	1959	2509	3712	4388	4761
6	Finance costs	526	536	471	1062	1024	2054
7	Profit (loss) from ordinary activities after finance costs but before exceptional items	1227	1423	2038	2650	3364	2707
8	Prior period items before tax	0	0	0	0	0	-251
9	Exceptional items	0	0	0	0	0	0
10	Profit (loss) from ordinary activities before tax	1227	1423	2038	2650	3364	2456
11	Tax Expense	200	200	400	400	600	790
12	Net profit (loss) from ordinary activities after tax	1027	1223	1638	2250	2764	1666
13	Extraordinary items	0	0	0	0	0	0
14	Net Profit Loss for the period from continuing operations	1027	1223	1638	2250	2764	1666
15	Profit (loss) from discontinuing operations before tax	0	0	0	0	0	0
16	Tax expense of discontinuing operations	0	0	0	0	0	0
17	Net profit (loss) from discontinuing operation after tax	0	0	0	0	0	0
18	Profit (loss) for period before minority interest	1027	1223	1638	2250	2764	1666
21	Net Profit (loss) after taxes minority interest and share of profit (loss) of associates	1027	1223	1638	2250	2764	1666

Quarterly & Half Yearly Financial Result by Companies Other than Banks							
Particulars		3 months ended (dd-mm-yyyy)	Previous 3 months ended (dd-mm-yyyy)	Corresponding 3 months ended in the previous year (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	Year to date figures for previous period ended (dd-mm-yyyy)	Previous accounting year ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2016	01-04-2016	01-07-2015	01-04-2016	01-04-2015	01-04-2015
B	Date of end of reporting period	30-09-2016	30-06-2016	30-09-2015	30-09-2016	30-09-2015	31-03-2016
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalone
Part I							
22	Details of equity share capital						
	Paid-up equity share capital	50717	50717	50717	50717	50717	50717
	Face value of equity share capital	10	10	10	10	10	10
23	Details of debt securities						
24	Reserves excluding revaluation reserve	18333	15684	14018	18333	14018	15684
26	Earnings per share						
i	Earnings per share before extraordinary items						
	Basic earnings per share before extraordinary items	0.202	0.241	0.32	0.443	0.54	0.328
	Diluted earnings per share before extraordinary items	0.202	0.241	0.32	0.443	0.54	0.328
ii	Earnings per share after extraordinary items						
	Basic earnings per share after extraordinary items	0.202	0.241	0.32	0.443	0.54	0.328
	Diluted earnings per share after extraordinary items	0.202	0.241	0.32	0.443	0.54	0.328
30	Disclosure of notes on financial results	Textual Information(1)					

Text Block	
Textual Information(1)	<ol style="list-style-type: none">1. The Standalone results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 5th Nov. 2016.2. In accordance with the requirements of Clause 41 of the Listing Agreement with the Stock Exchange, the Statutory Auditors have performed a limited review of the Companys financial results for the quarter ended Sep. 30, 2016 there are no qualifications.3. The Income from Operations is from one segment namely Pharmaceutical Industrty.4. Previous period exp. have been regrouped / rearranged, wherever necessary.5. taxes and depreciation are calculated on proportionate basis on annual estimated basis.6. There were no Investors complaints pending at the beginning of the quarter and one complaint were received during the quarter ended Sep. 30, 2016.

Statement of Asset and Liabilities		
Particulars	Half year ended (dd-mm-yyyy)	Previous year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2016	01-04-2015
Date of end of reporting period	30-09-2016	31-03-2016
Whether results are audited or unaudited	Unaudited	Audited
Nature of report standalone or consolidated	Standalone	Standalone
Equity and liabilities		
1 Shareholders' funds		
Share capital	50937	50937
Reserves and surplus	18333	15684
Money received against share warrants		
Total shareholders' funds	69270	66621
2 Share application money pending allotment	0	0
3 Deferred government grants	0	0
5 Non-current liabilities		
Long-term borrowings	0	35
Deferred tax liabilities (net)		
Foreign currency monetary item translation difference liability account		
Other long-term liabilities		
Long-term provisions	2179	2179
Total non-current liabilities	2179	2214
6 Current liabilities		
Short-term borrowings	17098	16747
Trade payables	4277	7428
Other current liabilities	3652	7442
Short-term provisions	2441	1040
Total current liabilities	27468	32657
Total equity and liabilities	98917	101492
Assets		
1 Non-current assets		
(i) Fixed assets		
Tangible assets	24809	24400
Producing properties		
Intangible assets	43	43
Preproducing properties		
Tangible assets capital work-in-progress		
Intangible assets under development or work-in-progress		
Total fixed assets	24852	24443

Statement of Asset and Liabilities			
Particulars		Half year ended (dd-mm-yyyy)	Previous year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2016	01-04-2015
Date of end of reporting period		30-09-2016	31-03-2016
Whether results are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
(ii)	Non-current investments	6784	6784
(v)	Deferred tax assets (net)	2442	2442
(vi)	Foreign currency monetary item translation difference asset account		
(vii)	Long-term loans and advances	7938	8085
(viii)	Other non-current assets		
Total non-current assets		42016	41754
Current assets			
	Current investments	0	0
	Inventories	17352	15423
	Trade receivables	34191	35783
	Cash and bank balances	1084	6316
	Short-term loans and advances	1550	1492
	Other current assets	2724	724
Total current assets		56901	59738
Total assets		98917	101492
Disclosure of notes on assets and liabilities			

